Development and validation of a LC/MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 874, Issue 1-2, 2008, Pages 57-63

  Handy, Russell ^a   Trepanier, Dan ^a   Scott, Grace ^a   Foster, Robert ^a   Freitag, Derrick ^a,b  

^a Isotechnika Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cyclosporine A; Immunosuppressant; ISA247; LC MS MS; Therapeutic drug monitoring; Voclosporin

Indexed keywords

BLOOD; CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHANOL; PATIENT MONITORING;

CYCLOSPORINE A; IMMUNOSUPPRESSANT; ISA247; LC/MS/MS; THERAPEUTIC DRUG MONITORING; VOCLOSPORIN;

LIQUID CHROMATOGRAPHY;

ACETIC ACID; ACETONITRILE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; ISA 247; METHANOL; UNCLASSIFIED DRUG; VOCLOSPORIN; WATER;

ACCURACY; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STANDARD; SUPERNATANT; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CALCINEURIN; CHROMATOGRAPHY, LIQUID; CYCLOSPORINE; HUMANS; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 53249111167     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.08.023     Document Type: Article

References (12)

1. Sketris I., Yatscoff R., Keown P., Canafax D.M., First M.R., Holt D.W., Schroeder T.J., and Wright M. Clin. Biochem. 28 (1995) 195
2. Aspeslet L., Freitag D., Trepanier D., Abel M., Naicker S., Kneteman N., Foster R., and Yatscoff R. Transplant. Proc. 33 (2001) 1048
3. Birsan T., Dambrin C., Freitag D.G., Yatscoff R.W., and Morris R.E. Transplant. Int. 17 (2005) 767
4. Gregory C.R., Kyles A.E., Bernsteen L., Wagner G.S., Tarantal A.F., Christe K.L., Brignolo L., Spinner A., Griffey S.M., Paniagua R.T., Hubble R.W., Borie D.C., and Morris R.E. Transplantation 78 (2004) 681
5. Maksymowych W.P., Jhangri G.S., Aspeslet L., Abel M.D., Trepanier D.J., Naicker S., Freitag D.G., Cooper B.L., Foster R.T., and Yatscoff R.W. J. Rheumatol. 29 (2002) 1646
6. Yatscoff R.W., Abel M.D., Aspeslet L.J., Foster R.T., Freitag D.G., Huizinga R.B., Mayo P.R., and Trepanier D.J. Am. J. Transplant. 3 s5 (2003) 463
7. Bissonnette R., Pap K., Poulin Y., Lauzon G., Aspeslet L., Huizinga R., Mayo P., Foster R.T., Yatscoff R.W., and Maksymowych W.P. J. Am. Acad. Dermatol. 54 (2006) 472
8. Wong S.H. Clin. Chim. Acta 313 (2001) 241
9. Touw D.J., Neef C., Thomson A.H., and Vinks A.A. Ther. Drug Monit. 27 (2005) 10
10. Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001.
11. Yang Z., Peng Y., and Wang S. Clin. Appl. Immunol. Rev. 5 (2005) 405
12. Matuszewski B.K. J. Chromatogr. B 830 (2006) 293